Seres Therapeutics (MCRB)


Market Price (11/10/2026): $1.71 | Market Cap: $17.4 MilSector: Health Care | Industry: Biotechnology

Seres Therapeutics (MCRB)


Market Price (11/10/2026): $1.71
Market Cap: $17.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics. Themes include Microbiome Therapeutics Development, and Infectious Disease Microbiome Therapies.

Weak multi-year price returns
2Y Excs Rtn is -119%, 3Y Excs Rtn is -162%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -66 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8390%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 108%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1085%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8104%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8108%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -282%

Key risks
MCRB key risks include [1] a significant funding shortfall raising substantial doubt about its ability to continue as a going concern, Show more.

0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics. Themes include Microbiome Therapeutics Development, and Infectious Disease Microbiome Therapies.
2 Weak multi-year price returns
2Y Excs Rtn is -119%, 3Y Excs Rtn is -162%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -66 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8390%
4 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 108%
5 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1085%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8104%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8108%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -282%
8 Key risks
MCRB key risks include [1] a significant funding shortfall raising substantial doubt about its ability to continue as a going concern, Show more.

MCRB in ETFs

Weight = MCRB's share of each fund

VTI0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 11/9/2026

Seres Therapeutics (MCRB) stock has lost about 65% since 7/31/2026 because of the following key factors:

1. Seres Therapeutics issued a "going concern" warning and reported a substantial net loss in fiscal Q3 2026.

The company's fiscal Q3 2026 report, which ended September 30, 2026, indicated substantial doubt about its ability to continue operations beyond fiscal Q1 2027 without securing additional funding. Seres Therapeutics reported a net loss of $16.3 million for fiscal Q3 2026, a significant downturn compared to a net income of $8.2 million in the prior-year quarter, which had benefited from a $27.2 million gain on the sale of its VOWST business. Cash and cash equivalents were $17.5 million as of September 30, 2026.

2. The company missed fiscal Q3 2026 earnings per share (EPS) and revenue consensus estimates.

For fiscal Q3 2026, Seres Therapeutics reported a diluted EPS of -$1.63, missing the consensus estimate of -$1.00. Additionally, revenue for the quarter was $593 thousand, falling significantly short of the consensus estimate of $6.35 million. This revenue miss is primarily attributed to the company's strategic shift to a clinical-stage model following the divestiture of VOWST.

Show more
Updated on 11/9/2026

Seres Therapeutics (MCRB) stock has lost about 65% since 7/31/2026 because of the following key factors:

1. Seres Therapeutics issued a "going concern" warning and reported a substantial net loss in fiscal Q3 2026.

The company's fiscal Q3 2026 report, which ended September 30, 2026, indicated substantial doubt about its ability to continue operations beyond fiscal Q1 2027 without securing additional funding. Seres Therapeutics reported a net loss of $16.3 million for fiscal Q3 2026, a significant downturn compared to a net income of $8.2 million in the prior-year quarter, which had benefited from a $27.2 million gain on the sale of its VOWST business. Cash and cash equivalents were $17.5 million as of September 30, 2026.

2. The company missed fiscal Q3 2026 earnings per share (EPS) and revenue consensus estimates.

For fiscal Q3 2026, Seres Therapeutics reported a diluted EPS of -$1.63, missing the consensus estimate of -$1.00. Additionally, revenue for the quarter was $593 thousand, falling significantly short of the consensus estimate of $6.35 million. This revenue miss is primarily attributed to the company's strategic shift to a clinical-stage model following the divestiture of VOWST.

3. A key clinical development program, SER-155, has its Phase 2 study paused pending funding.

Despite promising Phase 1b results for SER-155, showing a 77% relative risk reduction in bloodstream infections for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), the initiation of its Phase 2 study is currently paused due to a lack of funding. The company is actively seeking partnerships and capital to advance this critical pipeline asset.

4. Seres Therapeutics implemented workforce reductions and incurred lease termination charges as part of cost-cutting measures.

In an effort to conserve cash, Seres Therapeutics announced a workforce reduction of approximately 30% earlier in 2026. Furthermore, the company recorded a $5.7 million non-cash impairment of assets charge in fiscal Q3 2026, resulting from the early termination of a lease agreement for one of its Cambridge, Massachusetts facilities, as it continued to reduce ongoing facility-related cash costs.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -64.8% change in MCRB stock from 7/31/2026 to 11/9/2026 was primarily driven by a -63.3% change in the company's P/S Multiple.
(LTM values as of)731202611092026Change
Stock Price ($)4.831.70-64.8%
Change Contribution By: 
Total Revenues ($ Mil)110.0%
P/S Multiple58.721.5-63.3%
Shares Outstanding (Mil)1010-4.0%
Cumulative Contribution-64.8%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/9/2026
ReturnCorrelation
MCRB-64.8% 
Market (SPY)0.8%14.1%
Sector (XLV)15.9%19.1%

Fundamental Drivers

The -76.9% change in MCRB stock from 4/30/2026 to 11/9/2026 was primarily driven by a -75.1% change in the company's P/S Multiple.
(LTM values as of)430202611092026Change
Stock Price ($)7.371.70-76.9%
Change Contribution By: 
Total Revenues ($ Mil)110.0%
P/S Multiple86.221.5-75.1%
Shares Outstanding (Mil)910-7.5%
Cumulative Contribution-76.9%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/9/2026
ReturnCorrelation
MCRB-76.9% 
Market (SPY)5.0%11.0%
Sector (XLV)29.6%13.1%

Fundamental Drivers

The -89.4% change in MCRB stock from 10/31/2025 to 11/9/2026 was primarily driven by a null change in the company's P/S Multiple.
(LTM values as of)1031202511092026Change
Stock Price ($)16.101.70-89.4%
Change Contribution By: 
Total Revenues ($ Mil)019.2233720368547763E17%
P/S Multiple∞21.5 
Shares Outstanding (Mil)910-12.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/9/2026
ReturnCorrelation
MCRB-89.4% 
Market (SPY)11.3%15.5%
Sector (XLV)32.2%7.6%

Fundamental Drivers

The -94.4% change in MCRB stock from 10/31/2023 to 11/9/2026 was primarily driven by a -99.4% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311092026Change
Stock Price ($)30.601.70-94.4%
Change Contribution By: 
Total Revenues ($ Mil)1231-99.4%
P/S Multiple1.621.51256.5%
Shares Outstanding (Mil)610-36.0%
Cumulative Contribution-94.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/9/2026
ReturnCorrelation
MCRB-94.4% 
Market (SPY)86.2%10.7%
Sector (XLV)58.4%8.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MCRB Return-66%-33%-75%-41%-10%-89%-100%
Peers Return9%-9%4%-11%10%41%42%
S&P 500 Return27%-19%24%23%16%8%96%

Monthly Win Rates [3]
MCRB Win Rate50%50%33%50%50%36% 
Peers Win Rate52%50%55%43%50%58% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
MCRB Max Drawdown-81%-69%-86%-65%-98%-89% 
Peers Max Drawdown-29%-36%-30%-34%-30%-25% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALKS, ACT, LIVN, PRGO, PCRX. See MCRB Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/9/2026 (YTD)

How Low Can It Go

EventMCRBS&P 500
2025 US Tariff Shock
  % Loss-97.8%-18.8%
  % Gain to Breakeven4385.4%23.1%
  Time to Breakeven119 days79 days
2024 Yen Carry Trade Unwind
  % Loss-16.1%-7.8%
  % Gain to Breakeven19.2%8.5%
  Time to Breakeven27 days18 days
2022 Inflation Shock & Fed Tightening
  % Loss-69.5%-24.5%
  % Gain to Breakeven227.4%32.4%
  Time to Breakeven139 days427 days
2020 COVID-19 Crash
  % Loss-26.9%-33.7%
  % Gain to Breakeven36.7%50.9%
  Time to Breakeven19 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-38.8%-19.2%
  % Gain to Breakeven63.3%23.8%
  Time to Breakeven588 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-31.9%-3.7%
  % Gain to Breakeven46.8%3.9%
  Time to Breakeven218 days6 days

Compare to ALKS, ACT, LIVN, PRGO, PCRX

In The Past

Seres Therapeutics's stock fell -97.8% during the 2025 US Tariff Shock. Such a loss loss requires a 4385.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventMCRBS&P 500
2025 US Tariff Shock
  % Loss-97.8%-18.8%
  % Gain to Breakeven4385.4%23.1%
  Time to Breakeven119 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-69.5%-24.5%
  % Gain to Breakeven227.4%32.4%
  Time to Breakeven139 days427 days
2020 COVID-19 Crash
  % Loss-26.9%-33.7%
  % Gain to Breakeven36.7%50.9%
  Time to Breakeven19 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-38.8%-19.2%
  % Gain to Breakeven63.3%23.8%
  Time to Breakeven588 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-31.9%-3.7%
  % Gain to Breakeven46.8%3.9%
  Time to Breakeven218 days6 days

Compare to ALKS, ACT, LIVN, PRGO, PCRX

In The Past

Seres Therapeutics's stock fell -97.8% during the 2025 US Tariff Shock. Such a loss loss requires a 4385.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Seres Therapeutics (MCRB)

Seres Therapeutics, Inc. (MCRB) is a biotechnology company pioneering the development of microbiome therapeutics. The company's core business revolves around designing and advancing bacterial consortia, which are specific combinations of bacteria engineered to functionally interact with human host cells and tissues. This innovative platform aims to treat a range of diseases by harnessing the power of the human microbiome.

The company's lead product candidate, SER-109, is an oral microbiome therapeutic that has completed Phase III clinical trials for the treatment of recurrent Clostridium difficile infection (CDI), a severe gastrointestinal condition. Beyond CDI, Seres has a robust pipeline addressing other significant unmet medical needs. These include SER-155, in Phase Ib, designed to reduce gastrointestinal and bloodstream infections as well as graft-versus-host disease in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation and solid organ transplants. Other candidates, SER-287 and SER-301, are in Phase Ib for ulcerative colitis, and SER-401 is being developed for metastatic melanoma. Seres Therapeutics primarily serves patient populations with these serious conditions, often collaborating with partners like Nestec Ltd. and Memorial Sloan Kettering Cancer Center to advance its therapeutic solutions.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Seres Therapeutics:

  • Pfizer for the gut microbiome.
  • Moderna, but for developing microbiome-based drugs instead of mRNA vaccines.

AI Analysis | Feedback

  • SER-109: An oral microbiome therapeutic candidate that has completed Phase III clinical trials for the treatment of Clostridium difficile infection (CDI).
  • SER-155: A cultivated bacteria microbiome drug in Phase Ib clinical trial to reduce infections and graft versus host diseases in immunocompromised patients.
  • SER-287: A therapeutic candidate in Phase Ib to treat ulcerative colitis.
  • SER-301: A therapeutic candidate in Phase Ib to treat ulcerative colitis.
  • SER-401: A therapeutic candidate in development for patients with metastatic melanoma.
  • SER-262: A therapeutic candidate in development to treat Clostridioides difficile infection.

AI Analysis | Feedback

Seres Therapeutics (MCRB) is a biopharmaceutical company in the drug development phase. As such, it does not currently sell commercialized products directly to individuals, nor does it have major customers in the traditional sense of entities purchasing finished drugs for distribution or patient use. Its current business model involves developing therapeutic candidates and engaging in strategic partnerships for research, development, and potential future commercialization.

Based on the provided background, the company's major partners, who can be considered its "customers" or significant collaborators in a business-to-business context due to licensing and collaboration agreements, are:

  • Nestec Ltd. (a subsidiary of Nestlé S.A., symbol: NSRGY for its ADR, or NESN.SW on the SIX Swiss Exchange)
  • Memorial Sloan Kettering Cancer Center

AI Analysis | Feedback

  • Thermo Fisher Scientific (TMO)
  • Swissfillon AG

AI Analysis | Feedback

Richard N. Kender, Interim Chief Executive Officer and Executive Chair
Mr. Kender was appointed Executive Chair and Interim Chief Executive Officer of Seres Therapeutics, Inc. effective March 2, 2026. He has over 35 years of biopharma executive experience, including as Senior Vice President of Business Development and Corporate Licensing at Merck & Co. During his more than three-decade tenure at Merck, he held various roles across corporate development, including M&A, licensing, financial evaluation and analysis, and global competitive intelligence, and was involved in Merck's acquisition of Schering-Plough. Mr. Kender has served on the Seres Board of Directors since September 2014. He currently serves on the board of directors of Longeveron and has previously served on the boards of numerous public and private companies, including INC Research, Abide Therapeutics, ReViral, POXEL SA, Omega Therapeutics, and Bicycle Therapeutics.

Marella Thorell, Chief Financial Officer
Ms. Thorell serves as the Chief Financial Officer of Seres Therapeutics, Inc., a role she has held since joining the company in March 2024. She is a seasoned finance and operations expert with over 25 years of experience, including leading capital strategy, financial planning, accounting operations, building organizations, and preparing and executing IPOs. Prior to Seres, Ms. Thorell served as the Chief Financial Officer of Evelo Biosciences. Her previous roles also include Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of Palladio Biosciences, and Chief Financial Officer and Chief Operating Officer of Realm Therapeutics.

Thomas J. DesRosier, Chief Legal Officer
Mr. DesRosier serves as the Chief Legal Officer of Seres Therapeutics, Inc. He joined Seres in May 2016 as Executive Vice President, Chief Legal Officer and Secretary. Before joining Seres, he was the Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that, held the same position at Cubist Pharmaceuticals, where he led the negotiation of Cubist's acquisition by Merck. Mr. DesRosier also served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer.

Matthew Henn, Ph.D., President and Chief Scientific Officer
Dr. Henn is the President and Chief Scientific Officer of Seres Therapeutics, Inc. He is a long-tenured member of the Seres team and was instrumental in the development, approval, and launch of VOWST™ (formerly SER-109), which is the first-ever oral microbiome therapeutic.

Kelly Brady, M.S., Chief Operating Officer
Ms. Brady serves as the Chief Operating Officer of Seres Therapeutics, Inc. She previously held the role of Senior Vice President of Clinical Development. Ms. Brady is a long-tenured member of the Seres team and played a key role in the development, approval, and launch of VOWST™ (formerly SER-109), the first-ever oral microbiome therapeutic.

AI Analysis | Feedback

The key risks to Seres Therapeutics (MCRB) are primarily centered around its financial stability, the progression of its pipeline following the sale of its first approved product, and its reliance on a commercial partner.

  1. Financial Viability and Need for Additional Funding: Seres Therapeutics faces significant financial challenges, with "substantial doubt about its ability to continue as a going concern." The company has indicated a critical need for additional funding or strategic transactions to support its operations, having already reduced its workforce. Potential outcomes if funding is not secured include further cost reductions, partnership deals, or even seeking relief under the U.S. Bankruptcy Code.
  2. Clinical Trial Failures and Pipeline Dependence: Following the sale of VOWST (formerly SER-109), Seres Therapeutics' future growth is highly dependent on the successful development of its remaining pipeline candidates. Its new lead candidate, SER-155, has shown promising Phase 1b data and received Fast Track and Breakthrough Therapy designations. However, the planned Phase 2 trial for SER-155 is currently paused, awaiting additional financing. This highlights the inherent risks of clinical trial failures, delays in development, and the company's capacity to fund the progression of its early-stage programs.
  3. Reliance on Nestlé for VOWST Commercialization and Milestone Payments: Seres Therapeutics sold the commercial rights to its FDA-approved product, VOWST (previously SER-109), to Nestlé Health Science in 2024. While Seres has received upfront and will receive potential milestone payments, its future financial performance and strategic planning are now partially dependent on Nestlé's commercialization efforts and accurate reporting of VOWST net sales. Any inaccuracies or issues with Nestlé's reporting or commercial success could detrimentally impact Seres' financial statements and ability to realize expected milestone revenues.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here are the addressable market sizes for Seres Therapeutics' main products: * **For SER-109 (VOWST) and SER-262 (*Clostridioides difficile* infection (CDI)):** The global Clostridium difficile infection (CDI) treatment market is projected to reach approximately $2.87 billion by 2030, growing from $1.91 billion in 2024. Another estimate indicates the global Clostridium difficile Infections market size was valued at USD 9.82 billion in 2024 and is expected to reach USD 16.88 billion by 2032. The Clostridioides difficile infection market across the 7 Major Markets (7MM – United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was valued at approximately USD 551 million in 2025 and is projected to reach about USD 1,715 million by 2034. The United States accounted for the largest market share in 2024 within the 7MM. * **For SER-287 and SER-301 (Ulcerative Colitis):** The global ulcerative colitis market size was valued at USD 636.98 million in 2023 and is expected to grow to USD 9.72 billion by 2033. Another projection estimates the global ulcerative colitis market size to be valued at USD 8.70 billion in 2026 and reach USD 15.30 billion by 2033. The total ulcerative colitis market size in the 7MM was approximately USD 8,400 million in 2023, with the United States market alone accounting for approximately USD 5,900 million in the same year. * **For SER-401 (Metastatic Melanoma):** The global metastatic melanoma therapeutics market size is expected to reach $16.46 billion by 2030. In 2025, this market was valued at $9.29 billion and is projected to grow to $10.4 billion in 2026. Another report forecasts the metastatic melanoma market size to reach $14,950 million by 2030. The metastatic melanoma drugs market was valued at USD 4.94 billion in 2025 and is estimated to reach USD 8.7 billion by 2031. North America was the largest region in the metastatic melanoma therapeutics market in 2025 and held the largest market share with 37% of the overall market in 2023. * **For SER-155:** null

AI Analysis | Feedback

Seres Therapeutics (MCRB) is focusing its efforts on a streamlined pipeline following the sale of its lead commercial product, VOWST (formerly SER-109), to Nestlé Health Science in September 2024. While direct product sales of VOWST no longer contribute to Seres' revenue, several drivers are expected to fuel future growth over the next two to three years:

  1. VOWST (SER-109) Milestone and Profit-Sharing Payments: Despite the sale of VOWST's commercial rights, Seres Therapeutics is eligible to receive significant milestone payments based on VOWST's worldwide net sales performance. The company expects to receive approximately $73.5 million in payments in 2025 and is eligible for up to $275 million in future milestone payments tied to specific net sales targets. Seres also shares in the commercial profits and losses of VOWST.
  2. Upfront and Development Milestone Payments from Strategic Partnerships for SER-155: SER-155, an investigational oral microbiome therapeutic, is a primary focus for Seres and has received both FDA Fast Track and Breakthrough Therapy designations. Promising Phase 1b data showed a 77% relative risk reduction in bloodstream infections in immunocompromised patients, such as those undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Seres is actively seeking partnerships to advance SER-155 through its next clinical study (Phase 2). A significant upfront payment and subsequent development milestones from such a partnership would be a substantial revenue driver in the near term.
  3. Expansion of SER-155 into Additional Indications Leading to New Partnership Opportunities: Seres is exploring the potential of SER-155 in other medically vulnerable patient populations beyond allo-HSCT, including an investigator-sponsored trial for immune checkpoint inhibitor-related enterocolitis, with clinical data anticipated in the second quarter of 2026. Positive clinical data from these expanded indications could broaden the commercial appeal and market potential of SER-155, potentially leading to additional or expanded partnership deals that include upfront payments and milestone revenues.
  4. Early-Stage Partnerships for Other Pipeline Programs: Seres is also prioritizing other live biotherapeutic programs for inflammatory and immune diseases, such as SER-603 for inflammatory bowel disease. While these programs are in earlier stages of development, successful preclinical or early clinical data could attract collaboration interest from larger pharmaceutical companies. Such early-stage partnerships could provide Seres with upfront payments, research funding, and development milestones, contributing to revenue growth within the next two to three years.

AI Analysis | Feedback

Share Issuance

  • Seres Therapeutics raised net proceeds of $12.2 million in the fourth quarter of 2025 through an at-the-market (ATM) equity offering program.
  • The company's shares outstanding increased from 0.005 billion in 2021 to 0.009 billion by the third quarter of 2025, reflecting general issuance activity.

Inbound Investments

  • In September 2024, Seres Therapeutics completed the sale of its VOWST business to Nestlé Health Science, receiving approximately $175 million in gross proceeds, which included an upfront payment, a prepaid milestone, and an equity investment.
  • A $50 million installment payment related to the VOWST sale was received from Nestlé in January 2025, and a further $25 million installment was received in July 2025.
  • The company recognized an $80.7 million gain on the sale of its VOWST business in 2025.
  • Seres Therapeutics received up to $3.6 million in CARB-X funding.

Capital Expenditures

  • Capital expenditures were reported as -0.313 million (or -313K) in the last 12 months leading up to March 2026.
  • In the most recent quarter (prior to January 2026), capital expenditures totaled -0.0080 million.
  • For the years 2021, 2022, and 2023, capital expenditures were approximately -0.01 million each year.

Peer Outperformance in Biotechnology

MCRB has trailed 83% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that MCRB has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
7%
of 452 industry peers · -87.9% return
3Y
18%
of 398 industry peers · -91.6% return
5Y
17%
of 364 industry peers · -98.8% return
No Biotechnology peer with a comparable growth profile has beaten MCRB by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is MCRB's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 9.8%58.5%102.8% CAH 516% · MCK 395% · COR 192%
Health Care Services 20 34.0%25.5%10.9% HIMS 177% · RDNT 147% · DGX 101%
Managed Health Care 8 52.2%-4.3%-3.7% OSCR 98% · HQY 50% · ELV 5%
Health Care Facilities 26 23.0%20.7%-4.3% THC 263% · NHC 228% · EHC 190%
Health Care Equipment 50 11.7%22.1%-13.2% UFPT 383% · GKOS 358% · TMDX 202%
Pharmaceuticals 59 -11.8%20.4%-37.9% LQDA 1097% · XERS 709% · KNSA 590%
Health Care Supplies 11 29.2%20.4%-40.8% LNTH 235% · HAE 96% · MMSI 30%
Life Sciences Tools & Services 109 -0.8%-9.6%-74.3% AXGN 278% · MEDP 201% · NTRA 183%
Biotechnology ← 365 -21.2%-29.6%-80.6% ELVN 1218% · TRVI 1187% · DNTH 1113%
Health Care Technology 21 -19.4%-44.4%-82.6% VEEV -4% · DOCS -57%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

MCRBALKSACTLIVNPRGOPCRXMedian
NameSeres Th.Alkermes Enact LivaNova Perrigo Pacira B. 
Mkt Price1.7146.1546.6092.5916.7636.4841.31
Mkt Cap0.07.76.45.12.31.53.7
Rev LTM11,7541,2551,5074,0907431,381
Op Inc LTM-6691-1621842291
FCF LTM-64227713129168169169
FCF 3Y Avg-82344709143197162180
CFO LTM-64243713238241177239
CFO 3Y Avg-81380709216292174254

Growth & Margins

MCRBALKSACTLIVNPRGOPCRXMedian
NameSeres Th.Alkermes Enact LivaNova Perrigo Pacira B. 
Rev Chg LTM-15.3%2.5%11.7%-4.5%3.7%3.7%
Rev Chg 3Y Avg-3.7%3.4%10.5%-4.2%3.7%3.7%
Rev Chg Q-21.8%0.5%9.9%-5.2%-1.6%0.5%
QoQ Delta Rev Chg LTM0.0%5.2%0.1%2.4%-1.3%-0.4%0.1%
Op Inc Chg LTM36.0%-74.6%--16.4%-53.2%-57.7%-53.2%
Op Inc Chg 3Y Avg-12.0%-31.4%-90.3%4.6%39.9%4.6%
Op Mgn LTM-8,390.0%5.2%-10.7%4.5%3.0%4.5%
Op Mgn 3Y Avg-16.5%-10.9%6.4%8.3%9.6%
QoQ Delta Op Mgn LTM1,524.7%-3.4%--2.0%-1.5%0.5%-1.5%
CFO/Rev LTM-8,104.1%13.9%56.8%15.8%5.9%23.8%14.8%
CFO/Rev 3Y Avg-24.4%57.9%15.7%6.9%24.3%24.3%
FCF/Rev LTM-8,107.7%13.0%56.8%8.6%4.1%22.7%10.8%
FCF/Rev 3Y Avg-22.1%57.9%10.5%4.6%22.6%22.1%

Valuation

MCRBALKSACTLIVNPRGOPCRXMedian
NameSeres Th.Alkermes Enact LivaNova Perrigo Pacira B. 
Mkt Cap0.07.76.45.12.31.53.7
P/S21.64.45.13.40.62.03.9
P/Op Inc-0.385.0-31.512.765.831.5
P/EBIT0.579.17.033.6-1.529.718.4
P/E-0.4-22,072.19.426.0-1.338.54.5
P/CFO-0.331.99.021.49.78.29.3
Total Yield-276.7%-0.0%12.6%3.8%-68.1%2.6%1.3%
Dividend Yield0.0%0.0%2.0%0.0%6.8%0.0%0.0%
FCF Yield 3Y Avg-799.6%6.7%12.3%4.5%7.1%18.6%6.9%
D/E2.10.20.10.11.40.20.2
Net D/E1.10.1-0.3-0.01.20.00.1

Returns

MCRBALKSACTLIVNPRGOPCRXMedian
NameSeres Th.Alkermes Enact LivaNova Perrigo Pacira B. 
1M Rtn-36.9%13.6%1.4%21.2%11.3%0.5%6.3%
3M Rtn-65.8%-6.6%-3.5%21.1%35.3%49.3%8.8%
6M Rtn-78.2%30.1%9.9%32.1%58.5%60.4%31.1%
12M Rtn-87.8%40.3%28.6%83.5%27.0%65.4%34.5%
3Y Rtn-91.6%108.6%84.6%102.2%-29.9%28.1%56.3%
1M Excs Rtn-31.3%19.2%6.9%26.8%16.8%6.0%11.9%
3M Excs Rtn-58.6%-1.7%-0.1%22.4%37.6%54.2%11.1%
6M Excs Rtn-77.7%30.6%10.4%32.6%59.0%60.9%31.6%
12M Excs Rtn-97.5%35.9%19.8%77.0%13.2%63.1%27.8%
3Y Excs Rtn-162.1%31.4%12.4%19.4%-98.6%-45.9%-16.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment100 145
Collaboration revenue - related party   7 
Total1007145


Net Income by Segment
$ Mil2025202420232022
Single Segment60-114-250
Total60-114-250


Price Behavior

Price Behavior
Market Price$1.70 
Market Cap ($ Bil)0.0 
First Trading Date06/26/2015 
Distance from 52W High-94.1% 
   50 Days200 Days
DMA Price$3.27$6.70
DMA Trenddowndown
Distance from DMA-48.0%-74.6%
 3M1YR
Volatility76.4%91.4%
Downside Capture372.57296.45
Upside Capture-36.4835.24
Correlation (S&P 500)20.3%19.4%
MCRB Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.811.762.291.091.378.69
Up Beta5.942.912.172.880.7819.89
Down Beta3.722.563.00-0.021.550.24
Up Capture-416%-190%-35%-58%11%1765%
Bmk +ve Days12182862130427
Stock +ve Days5102148111344
Down Capture444%438%396%225%175%114%
Bmk -ve Days10253664121325
Stock -ve Days17324277139395

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MCRB
MCRB-87.8%91.4%-1.84-
Sector ETF (XLV)30.8%17.0%1.408.0%
Equity (SPY)13.3%13.7%0.6516.0%
Gold (GLD)3.7%28.8%0.1213.0%
Commodities (DBC)38.2%21.3%1.420.2%
Real Estate (VNQ)13.7%14.3%0.656.9%
Bitcoin (BTCUSD)-25.3%43.6%-0.5511.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MCRB
MCRB-57.9%938.0%0.39-
Sector ETF (XLV)8.8%15.4%0.377.4%
Equity (SPY)11.8%17.3%0.518.7%
Gold (GLD)17.8%19.1%0.75-2.9%
Commodities (DBC)8.0%19.6%0.290.7%
Real Estate (VNQ)1.5%18.9%-0.036.5%
Bitcoin (BTCUSD)4.4%51.6%0.277.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MCRB
MCRB-38.6%676.5%0.32-
Sector ETF (XLV)12.6%16.8%0.626.2%
Equity (SPY)15.3%18.0%0.727.5%
Gold (GLD)12.1%16.5%0.60-2.1%
Commodities (DBC)7.6%18.1%0.331.5%
Real Estate (VNQ)6.1%20.7%0.255.3%
Bitcoin (BTCUSD)60.0%66.3%1.004.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10152026
Short Interest: Shares Quantity0.3 Mil
Short Interest: % Change Since 9302026-0.6%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest3.4 days
Basic Shares Quantity10.0 Mil
Short % of Basic Shares3.1%

Earnings Returns History

Updated 11/9/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20266.6%  
8/5/2026-4.7%-11.6%5.5%
5/5/2026-2.5%2.0%-6.8%
3/12/20261.3%1.1%-6.8%
11/5/2025-7.6%8.4%21.2%
8/6/2025-3.5%8.1%31.7%
5/7/2025-3.0%-13.8%-15.1%
3/13/2025-7.9%12.5%-16.2%
...
SUMMARY STATS   
# Positive698
# Negative201617
Median Positive6.1%8.1%23.3%
Median Negative-7.0%-13.9%-15.1%
Max Positive20.4%19.1%43.4%
Max Negative-35.2%-27.8%-36.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/20266.6%  
8/5/2026-4.7%-11.6%5.5%
5/5/2026-2.5%2.0%-6.8%
3/12/20261.3%1.1%-6.8%
11/5/2025-7.6%8.4%21.2%
8/6/2025-3.5%8.1%31.7%
5/7/2025-3.0%-13.8%-15.1%
3/13/2025-7.9%12.5%-16.2%
1/10/2025-0.7%-13.5%-7.6%
11/13/2024-11.1%3.7%29.6%
8/13/2024-7.0%6.6%18.0%
5/8/2024-32.5%-19.3%-23.1%
3/5/2024-7.0%-24.6%-36.4%
1/10/2024-15.4%-9.8%-27.6%
11/2/2023-35.2%-27.8%-25.7%
8/8/2023-6.9%-16.7%-30.8%
5/9/20230.2%-4.1%-3.6%
3/7/2023-1.6%-2.0%5.6%
11/2/2022-9.5%-15.0%-26.3%
8/3/20228.5%17.6%25.4%
5/4/2022-2.5%-18.4%-34.1%
3/1/2022-7.6%-17.6%-6.6%
11/10/202120.4%19.1%43.4%
8/3/2021-1.0%-1.0%-8.8%
5/4/20215.6%-1.5%-5.7%
3/2/2021-4.8%-13.9%-5.8%
SUMMARY STATS   
# Positive698
# Negative201617
Median Positive6.1%8.1%23.3%
Median Negative-7.0%-13.9%-15.1%
Max Positive20.4%19.1%43.4%
Max Negative-35.2%-27.8%-36.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/05/202610-Q
12/31/202503/12/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/13/202510-K
09/30/202411/13/202410-Q
06/30/202408/13/202410-Q
03/31/202405/08/202410-Q
12/31/202303/05/202410-K
09/30/202311/02/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/07/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/05/202610-Q
12/31/202503/12/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/13/202510-K
09/30/202411/13/202410-Q
06/30/202408/13/202410-Q
03/31/202405/08/202410-Q
12/31/202303/05/202410-K
09/30/202311/02/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/07/202310-K
09/30/202211/02/202210-Q
06/30/202208/03/202210-Q
03/31/202205/04/202210-Q
12/31/202103/01/202210-K
09/30/202111/10/202110-Q
06/30/202108/03/202110-Q
03/31/202105/04/202110-Q
12/31/202003/02/202110-K
09/30/202011/09/202010-Q
06/30/202007/28/202010-Q
03/31/202005/07/202010-Q
12/31/201903/02/202010-K

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q1 2027 Cash RunwayReported     AffirmedGuidance: 0 for Q1 2027


Prior: Q1 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
Q3 2026 Cash RunwayReported     AffirmedGuidance: 0 for Q3 2026

Insider Activity

Updated 8/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Brady, KellySee RemarksDirectSell81820264.556429139,489Form
2Shaff, Eric D DirectSell81820264.552631,19756,870Form
3Henn, Matthew RSee RemarksDirectSell81820264.558136936,377Form
4Desrosier, ThomasSee RemarksDirectSell81820264.558237336,932Form
5Shaff, Eric D DirectSell51920267.532591,95090,661Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Brady, KellySee RemarksDirectSell81820264.556429139,489Form
2Shaff, Eric D DirectSell81820264.552631,19756,870Form
3Henn, Matthew RSee RemarksDirectSell81820264.558136936,377Form
4Desrosier, ThomasSee RemarksDirectSell81820264.558237336,932Form
5Shaff, Eric D DirectSell51920267.532591,95090,661Form
6Desrosier, ThomasSee RemarksDirectSell51920267.537959559,894Form
7Brady, KellySee RemarksDirectSell51920267.535944464,472Form
8Henn, Matthew RSee RemarksDirectSell51920267.537758059,020Form
9Shaff, Eric D DirectSell21820268.472592,19498,057Form
10Young, Teresa LSee RemarksDirectSell21820268.477563572,478Form
11Desrosier, ThomasSee RemarksDirectSell21820268.477866165,973Form
12Henn, Matthew RSee RemarksDirectSell21820268.478975465,024Form
13Young, Teresa LSee RemarksDirectSell1118202517.301,04218,027145,337Form
14Shaff, Eric D DirectSell1118202517.302173,754192,255Form
15Desrosier, ThomasSee RemarksDirectSell1118202517.30761,315131,878Form
16Henn, Matthew RSee RemarksDirectSell1118202517.301,25721,746130,217Form
17Shaff, Eric D DirectSell819202516.652173,613176,640Form
18Desrosier, ThomasSee RemarksDirectSell819202516.65761,265124,126Form
19Henn, Matthew RSee RemarksDirectSell819202516.65731,21575,724Form
20Young, Teresa LSee RemarksDirectSell819202516.655998286,830Form

Investor Activity (13F)

Updated Nov 10, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Flagship Pioneering, LLC$10.3 Mil0.9%7Hold13F
Active Manager
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Flagship Pioneering, LLC$10.3 Mil0.9%7Hold13F
Core Cache Last Updated: 11/9/2026